[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9Jw23HPfEyNquroQDMaP92TEIDhaoq8noQX5Dj5bsNc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"King's College London",[4],498,false,103,10,11343056,13,429,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Anxiety",19,{"name":18,"count":19},"Depression",17,{"name":21,"count":22},"Healthy",16,{"name":24,"count":11},"Psychosis",{"name":26,"count":9},"Schizophrenia",{"name":28,"count":29},"Major Depressive Disorder",9,{"name":31,"count":32},"Stroke",8,{"name":34,"count":32},"Heart Failure",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04407650","Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus","2024-12-31","Metformin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05790330","Mind and Skin - the Neurocutaneous Axis in Atopic Eczema","2025-12-01","Methotrexate",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06224530","Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk","2026-02","Levetiracetam",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06309472","Trial of Mirtazapine for Depression in IBD","2026-04","Mirtazapine",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05723276","Psilocybin in Functional Neurological Disorder","2026-05","Psilocybin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07471347","Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1)","2026-12","delta-9-tetrahydrocannabinol",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06957808","Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia","2027-01-20","Diroximel fumarate",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06537921","Comorbid Obesity and Depression With an Anti-inflammatory Medication","2027-09-01","Minocycline 200mg",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06461208","A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis","2028-01-31","Encapsulated FMT",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06992531","Auto-immune Contribution in Symptom-based Sensory and Autonomic Disorders","2029-10","Blood Product",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,120,138,161,186,208,241,264,287,305,326,347,369,389,418,444,462,488,516,544,562,580,607,625,661,686,711,739,757,775,799,824,850,877,902,930,956,979,1004,1030,1057,1075,1101,1127,1145,1168,1192,1216,1241,1276,1312,1347,1365,1383,1406,1433,1461,1479,1497,1524,1542,1560,1583,1608,1626,1652,1670,1694,1719,1744,1762,1788,1806,1824,1850,1874,1898,1923,1949,1974,1992,2018,2050,2068,2094,2112,2137,2155,2180,2198,2224],{"intervention":40,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":118},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":39},[108],{"nctId":37,"briefTitle":38,"status":109,"phases":110,"primaryCompletion":39,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"ACTIVE_NOT_RECRUITING",[91],"2025-05-31","2021-07-01",64,[115],"Gestational Diabetes",[40,117],"Ursodeoxycholic Acid",{"trials":119,"activeCount":99},[],{"intervention":117,"totalTrials":95,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":136},{"trials":123,"activeCount":99},[],{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":95,"soonestReadout":39},[132],{"nctId":37,"briefTitle":38,"status":109,"phases":133,"primaryCompletion":39,"completion":111,"start":112,"enrollment":113,"conditions":134,"interventions":135},[91],[115],[40,117],{"trials":137,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":157,"NA":159},{"trials":141,"activeCount":99},[],{"trials":143,"activeCount":99},[],{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":95,"soonestReadout":79},[148],{"nctId":77,"briefTitle":78,"status":149,"phases":150,"primaryCompletion":79,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"RECRUITING",[90],"2028-06-30","2023-06-21",300,[155],"Liver Cirrhosis",[80],{"trials":158,"activeCount":99},[],{"trials":160,"activeCount":99},[],{"intervention":162,"totalTrials":95,"cells":163},"Empagliflozin 10mg OD",{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":182,"NA":184},{"trials":165,"activeCount":99},[],{"trials":167,"activeCount":99},[],{"trials":169,"activeCount":99},[],{"trials":171,"activeCount":95,"soonestReadout":177},[172],{"nctId":173,"briefTitle":174,"status":175,"phases":176,"primaryCompletion":177,"completion":177,"start":59,"enrollment":178,"conditions":179,"interventions":181},"NCT07533747","PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction","NOT_YET_RECRUITING",[90],"2031-05",100,[180],"Coronary Microvascular Dysfunction (CMD)",[162],{"trials":183,"activeCount":99},[],{"trials":185,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":202,"PHASE4":204,"NA":206},{"trials":189,"activeCount":99},[],{"trials":191,"activeCount":99},[],{"trials":193,"activeCount":95,"soonestReadout":54},[194],{"nctId":52,"briefTitle":53,"status":149,"phases":195,"primaryCompletion":54,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},[89],"2026-10","2024-05-01",76,[28,200],"Inflammatory Bowel Diseases",[55],{"trials":203,"activeCount":99},[],{"trials":205,"activeCount":99},[],{"trials":207,"activeCount":99},[],{"intervention":50,"totalTrials":209,"cells":210},2,{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":233},{"trials":212,"activeCount":99},[],{"trials":214,"activeCount":99},[],{"trials":216,"activeCount":99},[],{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":99},[221],{"nctId":222,"briefTitle":223,"status":224,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT04610879","Changing Agendas on Sleep, Treatment and Learning in Epilepsy","TERMINATED",[91],"2020-09-23","2019-08-02",5,[230],"Rolandic Epilepsy",[232,50],"Carbamazepine",{"trials":234,"activeCount":95,"soonestReadout":49},[235],{"nctId":47,"briefTitle":48,"status":149,"phases":236,"primaryCompletion":49,"completion":49,"start":237,"enrollment":238,"conditions":239,"interventions":240},[92],"2024-07-19",69,[24],[50],{"intervention":85,"totalTrials":95,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":244,"activeCount":99},[],{"trials":246,"activeCount":99},[],{"trials":248,"activeCount":99},[],{"trials":250,"activeCount":99},[],{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":95,"soonestReadout":84},[255],{"nctId":82,"briefTitle":83,"status":175,"phases":256,"primaryCompletion":84,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":263},[],"2030-10","2025-10",250,[261,262],"Postural Orthostatic Tachycardia Syndrome (POTS)","Fibromyalgia (FM)",[85],{"intervention":45,"totalTrials":95,"cells":265},{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":276},{"trials":267,"activeCount":99},[],{"trials":269,"activeCount":99},[],{"trials":271,"activeCount":99},[],{"trials":273,"activeCount":99},[],{"trials":275,"activeCount":99},[],{"trials":277,"activeCount":95,"soonestReadout":44},[278],{"nctId":42,"briefTitle":43,"status":149,"phases":279,"primaryCompletion":44,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},[],"2027-06-01","2023-03-10",90,[284],"Atopic Dermatitis",[45,286],"Dupilumab",{"intervention":286,"totalTrials":95,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":299},{"trials":290,"activeCount":99},[],{"trials":292,"activeCount":99},[],{"trials":294,"activeCount":99},[],{"trials":296,"activeCount":99},[],{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":95,"soonestReadout":44},[301],{"nctId":42,"briefTitle":43,"status":149,"phases":302,"primaryCompletion":44,"completion":280,"start":281,"enrollment":282,"conditions":303,"interventions":304},[],[284],[45,286],{"intervention":60,"totalTrials":95,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":317},{"trials":308,"activeCount":99},[],{"trials":310,"activeCount":99},[],{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":99},[],{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":95,"soonestReadout":59},[319],{"nctId":57,"briefTitle":58,"status":109,"phases":320,"primaryCompletion":59,"completion":59,"start":321,"enrollment":322,"conditions":323,"interventions":325},[92],"2024-02-14",24,[324],"Functional Neurological Disorder",[60],{"intervention":70,"totalTrials":95,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":329,"activeCount":99},[],{"trials":331,"activeCount":99},[],{"trials":333,"activeCount":99},[],{"trials":335,"activeCount":99},[],{"trials":337,"activeCount":99},[],{"trials":339,"activeCount":95,"soonestReadout":69},[340],{"nctId":67,"briefTitle":68,"status":149,"phases":341,"primaryCompletion":69,"completion":69,"start":342,"enrollment":343,"conditions":344,"interventions":346},[92],"2025-01-10",30,[345],"Schizophrenia Disorders",[70],{"intervention":75,"totalTrials":95,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":350,"activeCount":99},[],{"trials":352,"activeCount":99},[],{"trials":354,"activeCount":99},[],{"trials":356,"activeCount":99},[],{"trials":358,"activeCount":99},[],{"trials":360,"activeCount":95,"soonestReadout":74},[361],{"nctId":72,"briefTitle":73,"status":149,"phases":362,"primaryCompletion":74,"completion":74,"start":363,"enrollment":364,"conditions":365,"interventions":368},[92],"2024-10-01",35,[366,28,367],"Obesity","Inflammation",[75],{"intervention":65,"totalTrials":95,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":372,"activeCount":99},[],{"trials":374,"activeCount":99},[],{"trials":376,"activeCount":99},[],{"trials":378,"activeCount":99},[],{"trials":380,"activeCount":99},[],{"trials":382,"activeCount":95,"soonestReadout":64},[383],{"nctId":62,"briefTitle":63,"status":175,"phases":384,"primaryCompletion":64,"completion":64,"start":385,"enrollment":9,"conditions":386,"interventions":388},[92],"2026-03",[387],"Cannabis Intoxication",[65],{"intervention":390,"totalTrials":95,"cells":391},"Rituximab",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":416},{"trials":393,"activeCount":99},[],{"trials":395,"activeCount":99},[],{"trials":397,"activeCount":99},[],{"trials":399,"activeCount":99},[],{"trials":401,"activeCount":99},[402],{"nctId":403,"briefTitle":404,"status":405,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":415},"NCT00476164","Study of Rituximab to Treat Chronic Renal Transplant Rejection","COMPLETED",[91],"2015-05","2017-04","2007-01",62,[412,413,414],"Kidney Transplantation","Graft Rejection","Immunosuppression",[390],{"trials":417,"activeCount":99},[],{"intervention":419,"totalTrials":95,"cells":420},"Biomarker",{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":442},{"trials":422,"activeCount":99},[],{"trials":424,"activeCount":99},[],{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":99},[],{"trials":430,"activeCount":99},[431],{"nctId":432,"briefTitle":433,"status":224,"phases":434,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":440},"NCT02498977","Liver Immunosuppression Free Trial",[91],"2021-12-31","2015-10",116,[439],"Transplantation, Liver",[419,441],"Tacrolimus, cyclosporine and\u002For mycophenolic acid, mycophenolate mofetil or azathioprine",{"trials":443,"activeCount":99},[],{"intervention":441,"totalTrials":95,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":460},{"trials":447,"activeCount":99},[],{"trials":449,"activeCount":99},[],{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[456],{"nctId":432,"briefTitle":433,"status":224,"phases":457,"primaryCompletion":435,"completion":435,"start":436,"enrollment":437,"conditions":458,"interventions":459},[91],[439],[419,441],{"trials":461,"activeCount":99},[],{"intervention":463,"totalTrials":95,"cells":464},"IL-2",{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":473,"NA":486},{"trials":466,"activeCount":99},[],{"trials":468,"activeCount":99},[],{"trials":470,"activeCount":99},[],{"trials":472,"activeCount":99},[],{"trials":474,"activeCount":99},[475],{"nctId":476,"briefTitle":477,"status":224,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":485},"NCT02949492","Low-dose IL-2 for Treg Expansion and Tolerance (LITE)",[91],"2019-01-31","2017-12-12",6,[483,484],"Transplantation","Liver Diseases",[463],{"trials":487,"activeCount":99},[],{"intervention":489,"totalTrials":95,"cells":490},"Ibuprofen",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":514},{"trials":492,"activeCount":99},[],{"trials":494,"activeCount":99},[],{"trials":496,"activeCount":99},[],{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":99},[501],{"nctId":502,"briefTitle":503,"status":504,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":99,"conditions":509,"interventions":513},"NCT04334629","LIBERATE Trial in COVID-19","WITHDRAWN",[91],"2021-05-25","2021-09-25","2020-05-26",[510,511,512],"Coronavirus","Respiratory Distress Syndrome","SARS-CoV Infection",[489],{"trials":515,"activeCount":99},[],{"intervention":517,"totalTrials":95,"cells":518},"Memantine",{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":525,"PHASE4":527,"NA":542},{"trials":520,"activeCount":99},[],{"trials":522,"activeCount":99},[],{"trials":524,"activeCount":99},[],{"trials":526,"activeCount":99},[],{"trials":528,"activeCount":99},[529],{"nctId":530,"briefTitle":531,"status":532,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT00866060","Donepezil and Memantine in Moderate to Severe Alzheimer's Disease","UNKNOWN",[91],"2012-02","2013-06","2008-02",800,[539],"Moderate to Severe Alzheimer's Disease",[517,541],"Donepezil",{"trials":543,"activeCount":99},[],{"intervention":541,"totalTrials":95,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":560},{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":99},[556],{"nctId":530,"briefTitle":531,"status":532,"phases":557,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":558,"interventions":559},[91],[539],[517,541],{"trials":561,"activeCount":99},[],{"intervention":232,"totalTrials":95,"cells":563},{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":572,"NA":578},{"trials":565,"activeCount":99},[],{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":99},[],{"trials":571,"activeCount":99},[],{"trials":573,"activeCount":99},[574],{"nctId":222,"briefTitle":223,"status":224,"phases":575,"primaryCompletion":226,"completion":226,"start":227,"enrollment":228,"conditions":576,"interventions":577},[91],[230],[232,50],{"trials":579,"activeCount":99},[],{"intervention":581,"totalTrials":95,"cells":582},"Quetiapine",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":605},{"trials":584,"activeCount":99},[],{"trials":586,"activeCount":99},[],{"trials":588,"activeCount":99},[],{"trials":590,"activeCount":99},[],{"trials":592,"activeCount":99},[593],{"nctId":594,"briefTitle":595,"status":532,"phases":596,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":603},"NCT03004521","Lithium Versus Quetiapine in Treatment Resistant Depression",[91],"2021-04","2021-08","2016-11",276,[602],"Depressive Disorder, Treatment-Resistant",[581,604],"Lithium",{"trials":606,"activeCount":99},[],{"intervention":604,"totalTrials":95,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":623},{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":99},[],{"trials":614,"activeCount":99},[],{"trials":616,"activeCount":99},[],{"trials":618,"activeCount":99},[619],{"nctId":594,"briefTitle":595,"status":532,"phases":620,"primaryCompletion":597,"completion":598,"start":599,"enrollment":600,"conditions":621,"interventions":622},[91],[602],[581,604],{"trials":624,"activeCount":99},[],{"intervention":626,"totalTrials":209,"cells":627},"Riluzole",{"EARLY_PHASE1":628,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":657,"NA":659},{"trials":629,"activeCount":99},[630],{"nctId":631,"briefTitle":632,"status":532,"phases":633,"primaryCompletion":39,"completion":39,"start":634,"enrollment":635,"conditions":636,"interventions":640},"NCT06270108","The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia",[87],"2022-11-14",288,[637,638,639],"Treatment-resistant Schizophrenia","Treatment-responsive Schizophrenia","Healthy Controls",[626],{"trials":642,"activeCount":99},[],{"trials":644,"activeCount":99},[],{"trials":646,"activeCount":99},[647],{"nctId":648,"briefTitle":649,"status":224,"phases":650,"completion":651,"start":652,"enrollment":537,"conditions":653,"interventions":656},"NCT00211224","Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)",[90],"2004-11","2000-04",[654,655],"Multiple System Atrophy","Progressive Supranuclear Palsy",[626],{"trials":658,"activeCount":99},[],{"trials":660,"activeCount":99},[],{"intervention":662,"totalTrials":95,"cells":663},"Omalizumab",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":682,"NA":684},{"trials":665,"activeCount":99},[],{"trials":667,"activeCount":99},[],{"trials":669,"activeCount":99},[],{"trials":671,"activeCount":99},[672],{"nctId":673,"briefTitle":674,"status":532,"phases":675,"primaryCompletion":676,"start":677,"enrollment":678,"conditions":679,"interventions":681},"NCT01113437","Omalizumab in Non-atopic Asthma",[89,90],"2012-08","2010-04",40,[680],"Bronchial Asthma",[662],{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[],{"intervention":687,"totalTrials":95,"cells":688},"Faecal microbiota transplantation",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":707,"NA":709},{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":99},[],{"trials":694,"activeCount":99},[],{"trials":696,"activeCount":99},[697],{"nctId":698,"briefTitle":699,"status":405,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT02862249","Trial of Faecal Microbiota Transplantation in Cirrhosis",[90],"2019-09-30","2018-03-27",32,[705],"Cirrhosis of the Liver",[687],{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":99},[],{"intervention":712,"totalTrials":95,"cells":713},"Buprenorphine Injectable Product",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":735,"NA":737},{"trials":715,"activeCount":99},[],{"trials":717,"activeCount":99},[],{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[722],{"nctId":723,"briefTitle":724,"status":405,"phases":725,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":732},"NCT05164549","Extended-release Pharmacotherapy for Opioid Use Disorder",[90],"2022-04-29","2023-03-01","2019-08-06",342,[731],"Opiate Substitution Treatment",[712,733,734],"Methadone","Buprenorphine",{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[],{"intervention":733,"totalTrials":95,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":753,"NA":755},{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":99},[749],{"nctId":723,"briefTitle":724,"status":405,"phases":750,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":751,"interventions":752},[90],[731],[712,733,734],{"trials":754,"activeCount":99},[],{"trials":756,"activeCount":99},[],{"intervention":734,"totalTrials":95,"cells":758},{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":771,"NA":773},{"trials":760,"activeCount":99},[],{"trials":762,"activeCount":99},[],{"trials":764,"activeCount":99},[],{"trials":766,"activeCount":99},[767],{"nctId":723,"briefTitle":724,"status":405,"phases":768,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":769,"interventions":770},[90],[731],[712,733,734],{"trials":772,"activeCount":99},[],{"trials":774,"activeCount":99},[],{"intervention":776,"totalTrials":95,"cells":777},"Mesenchymal stromal cells",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":779,"activeCount":99},[],{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[784],{"nctId":785,"briefTitle":786,"status":532,"phases":787,"primaryCompletion":788,"completion":788,"start":789,"enrollment":9,"conditions":790,"interventions":792},"NCT02323789","Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa",[88,89],"2017-07","2015-06",[791],"Recessive Dystrophic Epidermolysis Bullosa",[776],{"trials":794,"activeCount":99},[],{"trials":796,"activeCount":99},[],{"trials":798,"activeCount":99},[],{"intervention":800,"totalTrials":95,"cells":801},"5 azacytidine",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":803,"activeCount":99},[],{"trials":805,"activeCount":99},[],{"trials":807,"activeCount":99},[808],{"nctId":809,"briefTitle":810,"status":405,"phases":811,"primaryCompletion":812,"start":813,"enrollment":678,"conditions":814,"interventions":817},"NCT00915785","Azacytidine for the Treatment of Myelodysplastic Syndromes\u002FAcute Myeloid Leukemia (MDS\u002FAML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities",[89],"2013-04","2005-11",[815,816],"Myelodysplastic Syndromes","Leukemia, Myeloid, Acute",[800],{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":99},[],{"trials":823,"activeCount":99},[],{"intervention":825,"totalTrials":95,"cells":826},"AZD0328",{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":844,"PHASE4":846,"NA":848},{"trials":828,"activeCount":99},[],{"trials":830,"activeCount":99},[],{"trials":832,"activeCount":99},[833],{"nctId":834,"briefTitle":835,"status":504,"phases":836,"primaryCompletion":837,"completion":838,"start":839,"enrollment":99,"conditions":840,"interventions":843},"NCT04810104","Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug",[89],"2024-01","2024-04","2022-10",[841,842],"Parkinson Disease","Mild Cognitive Impairment",[825],{"trials":845,"activeCount":99},[],{"trials":847,"activeCount":99},[],{"trials":849,"activeCount":99},[],{"intervention":851,"totalTrials":95,"cells":852},"Liraglutide",{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":857,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":854,"activeCount":99},[],{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[859],{"nctId":860,"briefTitle":861,"status":405,"phases":862,"primaryCompletion":863,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":870},"NCT02315001","Liraglutide to Improve corONary Haemodynamics During Exercise streSS",[89],"2015-03","2014-01",26,[867,868,869],"Ischaemic Heart Disease","Coronary Heart Disease","Chronic Stable Angina",[851],{"trials":872,"activeCount":99},[],{"trials":874,"activeCount":99},[],{"trials":876,"activeCount":99},[],{"intervention":878,"totalTrials":95,"cells":879},"Sorafenib",{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":881,"activeCount":99},[],{"trials":883,"activeCount":99},[],{"trials":885,"activeCount":99},[886],{"nctId":887,"briefTitle":888,"status":532,"phases":889,"primaryCompletion":890,"start":891,"enrollment":892,"conditions":893,"interventions":895},"NCT00794859","Sorafenib in Previously Treated Malignant Mesothelioma",[89],"2009-12","2008-10",54,[894],"Mesothelioma",[878],{"trials":897,"activeCount":99},[],{"trials":899,"activeCount":99},[],{"trials":901,"activeCount":99},[],{"intervention":903,"totalTrials":95,"cells":904},"Decitabine",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":924,"PHASE4":926,"NA":928},{"trials":906,"activeCount":99},[],{"trials":908,"activeCount":99},[],{"trials":910,"activeCount":99},[911],{"nctId":912,"briefTitle":913,"status":532,"phases":914,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":923},"NCT01133886","Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure",[89],"2012-09","2013-09","2010-09",50,[920,921,922],"Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome",[903],{"trials":925,"activeCount":99},[],{"trials":927,"activeCount":99},[],{"trials":929,"activeCount":99},[],{"intervention":931,"totalTrials":95,"cells":932},"Psilocybin assisted therapy",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[939],{"nctId":940,"briefTitle":941,"status":532,"phases":942,"primaryCompletion":943,"completion":944,"start":945,"enrollment":946,"conditions":947,"interventions":949},"NCT04959253","Psilocybin in Depression Resistant to Standard Treatments",[89],"2023-09-01","2023-11-01","2020-09-01",60,[948],"Treatment Resistant Depression",[931],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":99},[],{"trials":955,"activeCount":99},[],{"intervention":957,"totalTrials":95,"cells":958},"AML Cell Vaccine",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[963],{"nctId":964,"briefTitle":965,"status":532,"phases":966,"primaryCompletion":967,"completion":967,"start":968,"enrollment":9,"conditions":969,"interventions":970},"NCT02493829","B7.1\u002FIL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)",[88],"2020-05","2017-05",[816,815],[957],{"trials":972,"activeCount":99},[],{"trials":974,"activeCount":99},[],{"trials":976,"activeCount":99},[],{"trials":978,"activeCount":99},[],{"intervention":980,"totalTrials":95,"cells":981},"Natalizumab",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":996,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[986],{"nctId":987,"briefTitle":988,"status":405,"phases":989,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":994,"interventions":995},"NCT03093064","Inflammatory Response In Schizophrenia",[88],"2023-06-15","2023-08-07","2017-04-01",66,[26],[980],{"trials":997,"activeCount":99},[],{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"intervention":1005,"totalTrials":95,"cells":1006},"MultiPepT1De",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1008,"activeCount":99},[],{"trials":1010,"activeCount":99},[1011],{"nctId":1012,"briefTitle":1013,"status":405,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1021},"NCT02620332","Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)",[88],"2017-07-31","2018-04-06","2015-10-20",27,[1020],"Type 1 Diabetes",[1005],{"trials":1023,"activeCount":99},[],{"trials":1025,"activeCount":99},[],{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":99},[],{"intervention":1031,"totalTrials":95,"cells":1032},"Standard formulation",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1049,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":99},[1037],{"nctId":1038,"briefTitle":1039,"status":405,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":1044,"conditions":1045,"interventions":1047},"NCT05032807","Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation",[88],"2022-08-26","2022-09-10","2022-07-01",14,[1046],"Absorption; Chemicals",[1031,1048],"Novel formulation",{"trials":1050,"activeCount":99},[],{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"intervention":1048,"totalTrials":95,"cells":1058},{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1067,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":99},[1063],{"nctId":1038,"briefTitle":1039,"status":405,"phases":1064,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":1044,"conditions":1065,"interventions":1066},[88],[1046],[1031,1048],{"trials":1068,"activeCount":99},[],{"trials":1070,"activeCount":99},[],{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[],{"intervention":1076,"totalTrials":95,"cells":1077},"TR004",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1099},{"trials":1079,"activeCount":99},[],{"trials":1081,"activeCount":99},[1082],{"nctId":1083,"briefTitle":1084,"status":532,"phases":1085,"primaryCompletion":1086,"completion":1087,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1092},"NCT03185000","Treg Immunotherapy in Crohn's Disease",[88],"2024-03-31","2025-06-30","2022-08-08",4,[1091],"Crohn Disease",[1076],{"trials":1094,"activeCount":99},[],{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":99},[],{"intervention":1102,"totalTrials":95,"cells":1103},"L-dopa",{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1119,"PHASE3":1121,"PHASE4":1123,"NA":1125},{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[1108],{"nctId":1109,"briefTitle":1110,"status":405,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":343,"conditions":1114,"interventions":1118},"NCT03754062","Pharmacological Modulation of Belief Salience",[88],"2019-09-01","2017-06-01",[1115,1116,1117],"Haloperidol","Placebo","L-DOPA",[1102,1115],{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"intervention":1115,"totalTrials":95,"cells":1128},{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1130,"activeCount":99},[],{"trials":1132,"activeCount":99},[1133],{"nctId":1109,"briefTitle":1110,"status":405,"phases":1134,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":343,"conditions":1135,"interventions":1136},[88],[1115,1116,1117],[1102,1115],{"trials":1138,"activeCount":99},[],{"trials":1140,"activeCount":99},[],{"trials":1142,"activeCount":99},[],{"trials":1144,"activeCount":99},[],{"intervention":1146,"totalTrials":95,"cells":1147},"Gene-modified autologous fibroblasts",{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1166},{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[1152],{"nctId":1153,"briefTitle":1154,"status":405,"phases":1155,"primaryCompletion":1156,"completion":1156,"start":1157,"enrollment":228,"conditions":1158,"interventions":1159},"NCT02493816","Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa",[88],"2018-03","2015-09",[791],[1146],{"trials":1161,"activeCount":99},[],{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":99},[],{"intervention":1169,"totalTrials":95,"cells":1170},"Sodium Nitroprusside",{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1184,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1172,"activeCount":99},[],{"trials":1174,"activeCount":99},[1175],{"nctId":1176,"briefTitle":1177,"status":405,"phases":1178,"primaryCompletion":1179,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1183},"NCT02176044","The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study",[88],"2016-02","2014-08",21,[26],[1169],{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":99},[],{"intervention":1193,"totalTrials":95,"cells":1194},"Saracatinib",{"EARLY_PHASE1":1195,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1196,"activeCount":99},[1197],{"nctId":1198,"briefTitle":1199,"status":532,"phases":1200,"primaryCompletion":1201,"completion":1201,"start":1202,"enrollment":343,"conditions":1203,"interventions":1205},"NCT03661125","SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis",[87],"2021-09-01","2019-04-11",[1204],"Parkinson Disease Psychosis",[1193],{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[],{"trials":1213,"activeCount":99},[],{"trials":1215,"activeCount":99},[],{"intervention":1217,"totalTrials":95,"cells":1218},"Naltrexone",{"EARLY_PHASE1":1219,"PHASE1":1231,"PHASE2":1233,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1220,"activeCount":99},[1221],{"nctId":1222,"briefTitle":1223,"status":405,"phases":1224,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1018,"conditions":1228,"interventions":1229},"NCT04977674","Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine",[87],"2023-02-13","2023-02-20","2021-09-27",[602],[1217,1230],"Ketamine",{"trials":1232,"activeCount":99},[],{"trials":1234,"activeCount":99},[],{"trials":1236,"activeCount":99},[],{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[],{"intervention":1230,"totalTrials":209,"cells":1242},{"EARLY_PHASE1":1243,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1244,"activeCount":99},[1245],{"nctId":1222,"briefTitle":1223,"status":405,"phases":1246,"primaryCompletion":1225,"completion":1226,"start":1227,"enrollment":1018,"conditions":1247,"interventions":1248},[87],[602],[1217,1230],{"trials":1250,"activeCount":99},[],{"trials":1252,"activeCount":99},[],{"trials":1254,"activeCount":99},[],{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":99},[1259],{"nctId":1260,"briefTitle":1261,"status":405,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1274},"NCT05870501","Synaptic Imaging and Network Activity in Treatment Resistant Depression",[92],"2023-09-13","2021-10-20",56,[1267,1268,602,1269,1270,1271,1272,1273],"Depressive Disorder","Depressive Disorder, Major","Bipolar Disorder","Bipolar Disorder I","Bipolar Disorder II","Mood Disorders","Anhedonia",[1230,1275],"Midazolam",{"intervention":1277,"totalTrials":209,"cells":1278},"Cannabidiol",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1280,"activeCount":99},[],{"trials":1282,"activeCount":99},[],{"trials":1284,"activeCount":99},[],{"trials":1286,"activeCount":99},[],{"trials":1288,"activeCount":99},[],{"trials":1290,"activeCount":99},[1291,1302],{"nctId":1292,"briefTitle":1293,"status":405,"phases":1294,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT05170217","Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio",[92],"2019-06-09","2017-11-08",46,[1299],"Cannabis Use",[1301,1277,1277,1277],"THC",{"nctId":1303,"briefTitle":1304,"status":405,"phases":1305,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1310},"NCT04605393","Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study",[92],"2023-07-07","2021-01-01",36,[26,1299],[1277,1311],"Delta-9-THC",{"intervention":1313,"totalTrials":209,"cells":1314},"Naloxone",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1316,"activeCount":99},[],{"trials":1318,"activeCount":99},[1319],{"nctId":1320,"briefTitle":1321,"status":532,"phases":1322,"primaryCompletion":1323,"completion":1323,"start":1324,"enrollment":1089,"conditions":1325,"interventions":1328},"NCT02733822","Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study",[88],"2017-06","2016-06",[1326,1327],"Drug Overdose","Opioid-Related Disorders",[1313],{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[],{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[1337],{"nctId":1338,"briefTitle":1339,"status":532,"phases":1340,"primaryCompletion":1341,"completion":1341,"start":1342,"enrollment":1343,"conditions":1344,"interventions":1346},"NCT05072249","European Cohort Study of the Effectiveness of Take Home Naloxone",[],"2023-12-30","2021-06-08",6000,[1345],"Opioid Overdose",[1313],{"intervention":1275,"totalTrials":95,"cells":1348},{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1350,"activeCount":99},[],{"trials":1352,"activeCount":99},[],{"trials":1354,"activeCount":99},[],{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[1361],{"nctId":1260,"briefTitle":1261,"status":405,"phases":1362,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1363,"interventions":1364},[92],[1267,1268,602,1269,1270,1271,1272,1273],[1230,1275],{"intervention":1301,"totalTrials":95,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1368,"activeCount":99},[],{"trials":1370,"activeCount":99},[],{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[1379],{"nctId":1292,"briefTitle":1293,"status":405,"phases":1380,"primaryCompletion":1295,"completion":1295,"start":1296,"enrollment":1297,"conditions":1381,"interventions":1382},[92],[1299],[1301,1277,1277,1277],{"intervention":1384,"totalTrials":95,"cells":1385},"Standard care",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[],{"trials":1395,"activeCount":99},[],{"trials":1397,"activeCount":99},[1398],{"nctId":1399,"briefTitle":1400,"status":1401,"phases":1402,"primaryCompletion":1403,"completion":1403,"start":1157,"enrollment":678,"conditions":1404,"interventions":1405},"NCT02546024","Predictors of Treatment Response in Late-onset Major Depressive Disorder","SUSPENDED",[],"2017-11",[1268],[1384],{"intervention":1407,"totalTrials":95,"cells":1408},"GLP-1 receptor agonist",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1417,"NA":1419},{"trials":1410,"activeCount":99},[],{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":99},[],{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":99},[],{"trials":1420,"activeCount":99},[1421],{"nctId":1422,"briefTitle":1423,"status":532,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1432},"NCT05492305","Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health",[],"2023-06","2023-08","2022-09",20,[1430,366,1431],"Diabetes Mellitus","Mental Health Issue",[1407],{"intervention":1434,"totalTrials":95,"cells":1435},"PLC",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1444,"NA":1446},{"trials":1437,"activeCount":99},[],{"trials":1439,"activeCount":99},[],{"trials":1441,"activeCount":99},[],{"trials":1443,"activeCount":99},[],{"trials":1445,"activeCount":99},[],{"trials":1447,"activeCount":99},[1448],{"nctId":1449,"briefTitle":1450,"status":405,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1456,"interventions":1458},"NCT03537950","Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder",[92],"2017-02-16","2017-03-01","2016-08-22",38,[1457],"Autism Spectrum Disorder",[1434,1459,1460],"CBD","CBDV",{"intervention":1459,"totalTrials":95,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1464,"activeCount":99},[],{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[1475],{"nctId":1449,"briefTitle":1450,"status":405,"phases":1476,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1477,"interventions":1478},[92],[1457],[1434,1459,1460],{"intervention":1460,"totalTrials":95,"cells":1480},{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1487,"PHASE4":1489,"NA":1491},{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":99},[],{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[],{"trials":1490,"activeCount":99},[],{"trials":1492,"activeCount":99},[1493],{"nctId":1449,"briefTitle":1450,"status":405,"phases":1494,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1495,"interventions":1496},[92],[1457],[1434,1459,1460],{"intervention":1498,"totalTrials":95,"cells":1499},"Pre-hospital interventional care bundle",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1501,"activeCount":99},[],{"trials":1503,"activeCount":99},[],{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[],{"trials":1509,"activeCount":99},[],{"trials":1511,"activeCount":99},[1512],{"nctId":1513,"briefTitle":1514,"status":532,"phases":1515,"primaryCompletion":1516,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT03724214","Multi-Centre Gastroschisis Interventional Study Across Sub-Saharan Africa",[92],"2020-11-08","2021-01-31","2018-10-08",235,[1521],"Gastroschisis",[1498,1523],"In-hospital interventional care bundle",{"intervention":1523,"totalTrials":95,"cells":1525},{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":99},[],{"trials":1533,"activeCount":99},[],{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[1538],{"nctId":1513,"briefTitle":1514,"status":532,"phases":1539,"primaryCompletion":1516,"completion":1517,"start":1518,"enrollment":1519,"conditions":1540,"interventions":1541},[92],[1521],[1498,1523],{"intervention":1311,"totalTrials":95,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1545,"activeCount":99},[],{"trials":1547,"activeCount":99},[],{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[1556],{"nctId":1303,"briefTitle":1304,"status":405,"phases":1557,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":1558,"interventions":1559},[92],[26,1299],[1277,1311],{"intervention":1561,"totalTrials":95,"cells":1562},"Sativex Oromucosal Spray",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1564,"activeCount":99},[],{"trials":1566,"activeCount":99},[],{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[],{"trials":1572,"activeCount":99},[],{"trials":1574,"activeCount":99},[1575],{"nctId":1576,"briefTitle":1577,"status":405,"phases":1578,"primaryCompletion":789,"completion":1579,"start":1180,"enrollment":343,"conditions":1580,"interventions":1582},"NCT02249299","Experimental Medicine in ADHD - Cannabinoids",[92],"2015-12",[1581],"Attention Deficit Hyperactivity Disorder (ADHD)",[1561],{"intervention":1584,"totalTrials":95,"cells":1585},"Diazepam 5 Mg Oral",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1587,"activeCount":99},[],{"trials":1589,"activeCount":99},[],{"trials":1591,"activeCount":99},[],{"trials":1593,"activeCount":99},[],{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[1598],{"nctId":1599,"briefTitle":1600,"status":405,"phases":1601,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":322,"conditions":1604,"interventions":1606},"NCT06190483","Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk",[92],"2023-03-24","2019-07-24",[1605],"Prodromal Schizophrenia",[1584,1607],"Ascorbic Acid 50 Mg Oral",{"intervention":1607,"totalTrials":95,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1620},{"trials":1611,"activeCount":99},[],{"trials":1613,"activeCount":99},[],{"trials":1615,"activeCount":99},[],{"trials":1617,"activeCount":99},[],{"trials":1619,"activeCount":99},[],{"trials":1621,"activeCount":99},[1622],{"nctId":1599,"briefTitle":1600,"status":405,"phases":1623,"primaryCompletion":1602,"completion":1602,"start":1603,"enrollment":322,"conditions":1624,"interventions":1625},[92],[1605],[1584,1607],{"intervention":1627,"totalTrials":95,"cells":1628},"Lisdexamfetamine dimesylate",{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1630,"activeCount":99},[],{"trials":1632,"activeCount":99},[],{"trials":1634,"activeCount":99},[],{"trials":1636,"activeCount":99},[],{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[1641],{"nctId":1642,"briefTitle":1643,"status":532,"phases":1644,"primaryCompletion":1645,"completion":1646,"start":1647,"enrollment":1428,"conditions":1648,"interventions":1650},"NCT03333668","Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents",[92],"2022-12-31","2025-03-31","2018-10-01",[1649],"ADHD",[1627,1651],"Guanfacine Extended Release Oral",{"intervention":1651,"totalTrials":95,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1660,"PHASE4":1662,"NA":1664},{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[],{"trials":1659,"activeCount":99},[],{"trials":1661,"activeCount":99},[],{"trials":1663,"activeCount":99},[],{"trials":1665,"activeCount":99},[1666],{"nctId":1642,"briefTitle":1643,"status":532,"phases":1667,"primaryCompletion":1645,"completion":1646,"start":1647,"enrollment":1428,"conditions":1668,"interventions":1669},[92],[1649],[1627,1651],{"intervention":1671,"totalTrials":95,"cells":1672},"Intra venous fluid",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":99},[],{"trials":1684,"activeCount":99},[1685],{"nctId":1686,"briefTitle":1687,"status":532,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":343,"conditions":1691,"interventions":1693},"NCT03898674","Microcirculatory Guided Goal Directed Fluid Therapy in Septic Shock; a Feasibility Study",[92],"2020-10-01","2019-02-05",[1692],"Septic Shock",[1671],{"intervention":1695,"totalTrials":95,"cells":1696},"MMR vaccination",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1698,"activeCount":99},[],{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[],{"trials":1704,"activeCount":99},[],{"trials":1706,"activeCount":99},[],{"trials":1708,"activeCount":99},[1709],{"nctId":1710,"briefTitle":1711,"status":405,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1718},"NCT06456788","Barriers and Facilitators to MMR Vaccination Among Healthcare Workers",[],"2024-12-19","2024-09-12",23,[1717],"Measles",[1695],{"intervention":1720,"totalTrials":95,"cells":1721},"Citalopram",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[],{"trials":1731,"activeCount":99},[],{"trials":1733,"activeCount":99},[1734],{"nctId":1735,"briefTitle":1736,"status":532,"phases":1737,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":178,"conditions":1741,"interventions":1742},"NCT04145076","Brain Response to Serotonergic Medications in ASD",[92],"2023-02","2023-05-31","2014-12-15",[1457],[1720,1743],"Tianeptine",{"intervention":1743,"totalTrials":95,"cells":1745},{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1747,"activeCount":99},[],{"trials":1749,"activeCount":99},[],{"trials":1751,"activeCount":99},[],{"trials":1753,"activeCount":99},[],{"trials":1755,"activeCount":99},[],{"trials":1757,"activeCount":99},[1758],{"nctId":1735,"briefTitle":1736,"status":532,"phases":1759,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":178,"conditions":1760,"interventions":1761},[92],[1457],[1720,1743],{"intervention":1763,"totalTrials":95,"cells":1764},"AZD7325_10",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[],{"trials":1772,"activeCount":99},[],{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[1777],{"nctId":1778,"briefTitle":1779,"status":405,"phases":1780,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1783,"conditions":1784,"interventions":1785},"NCT03678129","GABA Pathways in Autism Spectrum Disorder (ASD)",[92],"2025-06-27","2018-12-07",109,[1457],[1763,1786,1787],"AZD7325_20","Clobazam",{"intervention":1786,"totalTrials":95,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1796,"PHASE4":1798,"NA":1800},{"trials":1791,"activeCount":99},[],{"trials":1793,"activeCount":99},[],{"trials":1795,"activeCount":99},[],{"trials":1797,"activeCount":99},[],{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[1802],{"nctId":1778,"briefTitle":1779,"status":405,"phases":1803,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1783,"conditions":1804,"interventions":1805},[92],[1457],[1763,1786,1787],{"intervention":1787,"totalTrials":95,"cells":1807},{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[1820],{"nctId":1778,"briefTitle":1779,"status":405,"phases":1821,"primaryCompletion":1781,"completion":1781,"start":1782,"enrollment":1783,"conditions":1822,"interventions":1823},[92],[1457],[1763,1786,1787],{"intervention":1825,"totalTrials":95,"cells":1826},"Drug Therapy for Heart Failure",{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1828,"activeCount":99},[],{"trials":1830,"activeCount":99},[],{"trials":1832,"activeCount":99},[],{"trials":1834,"activeCount":99},[],{"trials":1836,"activeCount":99},[],{"trials":1838,"activeCount":99},[1839],{"nctId":1840,"briefTitle":1841,"status":405,"phases":1842,"primaryCompletion":1843,"completion":1844,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1849},"NCT01920048","Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure",[92],"2020-03-19","2022-03-31","2013-08-28",700,[1848],"Ischemic Cardiomyopathy",[1825],{"intervention":1851,"totalTrials":95,"cells":1852},"JNJ-18038683",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1854,"activeCount":99},[],{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[1865],{"nctId":1866,"briefTitle":1867,"status":532,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":1871,"conditions":1872,"interventions":1873},"NCT03633357","Imaging 5HT7 Antagonist Effects in Bipolar Disorder",[92],"2022-06","2018-08-16",68,[1269],[1851],{"intervention":1875,"totalTrials":95,"cells":1876},"Glyceryl Trinitrate",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[],{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":99},[1889],{"nctId":1890,"briefTitle":1891,"status":405,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":16,"conditions":1895,"interventions":1897},"NCT02906553","The Role of Nitric Oxide in Cognition in Schizophrenia",[92],"2019-04","2016-09",[26,1896],"Psychotic Disorders",[1875],{"intervention":1899,"totalTrials":95,"cells":1900},"Intravenous",{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1902,"activeCount":99},[],{"trials":1904,"activeCount":99},[],{"trials":1906,"activeCount":99},[],{"trials":1908,"activeCount":99},[],{"trials":1910,"activeCount":99},[],{"trials":1912,"activeCount":99},[1913],{"nctId":1914,"briefTitle":1915,"status":405,"phases":1916,"primaryCompletion":1917,"completion":1917,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1922},"NCT04656886","Ketamine's Actions on Rumination Mechanisms as an Antidepressant",[92],"2018-05","2014-09",37,[1921],"Remission in Depression",[1899],{"intervention":1924,"totalTrials":95,"cells":1925},"Memantine Hydrochloride",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1934,"NA":1936},{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[],{"trials":1935,"activeCount":99},[],{"trials":1937,"activeCount":99},[1938],{"nctId":1939,"briefTitle":1940,"status":532,"phases":1941,"start":1942,"enrollment":1943,"conditions":1944,"interventions":1948},"NCT00240760","Memantine and Down's Syndrome",[92],"2005-10",180,[1945,1946,1947],"Down's Syndrome","Dementia","Learning Disabilities",[1924],{"intervention":1950,"totalTrials":95,"cells":1951},"Psilocybin 5 mg",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1962},{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[],{"trials":1959,"activeCount":99},[],{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[1964],{"nctId":1965,"briefTitle":1966,"status":405,"phases":1967,"primaryCompletion":1968,"completion":1968,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1972},"NCT05651126","Psilocybin in Adults With and Without Autism Spectrum Disorder",[92],"2024-08-23","2022-12-12",67,[1457],[1950,1973],"Psilocybin 2 mg",{"intervention":1973,"totalTrials":95,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"trials":1983,"activeCount":99},[],{"trials":1985,"activeCount":99},[],{"trials":1987,"activeCount":99},[1988],{"nctId":1965,"briefTitle":1966,"status":405,"phases":1989,"primaryCompletion":1968,"completion":1968,"start":1969,"enrollment":1970,"conditions":1990,"interventions":1991},[92],[1457],[1950,1973],{"intervention":1993,"totalTrials":95,"cells":1994},"Oxytocin nasal spray",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2005},{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[2007],{"nctId":2008,"briefTitle":2009,"status":405,"phases":2010,"primaryCompletion":2011,"completion":2012,"start":2013,"enrollment":2014,"conditions":2015,"interventions":2017},"NCT05383300","Intranasal Oxytocin in Antiosocial Personality Disorder and Psychopathy",[92],"2020-03-01","2021-12-01","2017-05-01",72,[2016],"Antisocial Personality Disorder",[1993],{"intervention":2019,"totalTrials":95,"cells":2020},"COVID infection",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2022,"activeCount":99},[],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[2033],{"nctId":2034,"briefTitle":2035,"status":532,"phases":2036,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2048},"NCT05212766","Role of the Oral Microbiome & Mucosal Immunity in COVID-19 Disease",[],"2023-10-30","2024-12-30","2022-04-07",750,[2042,2043,2044,2045,2046,2047],"COVID-19","Microbial Colonization","Oral Disease","Periodontal Diseases","Innate Inflammatory Response","Mucosal Infection",[2019,2049],"COVID vaccination",{"intervention":2049,"totalTrials":95,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2053,"activeCount":99},[],{"trials":2055,"activeCount":99},[],{"trials":2057,"activeCount":99},[],{"trials":2059,"activeCount":99},[],{"trials":2061,"activeCount":99},[],{"trials":2063,"activeCount":99},[2064],{"nctId":2034,"briefTitle":2035,"status":532,"phases":2065,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":2040,"conditions":2066,"interventions":2067},[],[2042,2043,2044,2045,2046,2047],[2019,2049],{"intervention":2069,"totalTrials":95,"cells":2070},"Mindfulness training + real tDCS",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2079,"NA":2081},{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[],{"trials":2080,"activeCount":99},[],{"trials":2082,"activeCount":99},[2083],{"nctId":2084,"briefTitle":2085,"status":405,"phases":2086,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2092},"NCT05865912","A Feasibility Study of Mindfulness Training Transcranial Direct Current Stimulation (tDCS) in Adults With Overweight and Obesity",[92],"2025-02-19","2023-10-17",52,[2091],"Adults With Overweight and Obesity",[2069,2093],"Mindfulness training + sham tDCS",{"intervention":2093,"totalTrials":95,"cells":2095},{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2102,"PHASE4":2104,"NA":2106},{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[],{"trials":2107,"activeCount":99},[2108],{"nctId":2084,"briefTitle":2085,"status":405,"phases":2109,"primaryCompletion":2087,"completion":2087,"start":2088,"enrollment":2089,"conditions":2110,"interventions":2111},[92],[2091],[2069,2093],{"intervention":2113,"totalTrials":95,"cells":2114},"Arbaclofen_15",{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[],{"trials":2120,"activeCount":99},[],{"trials":2122,"activeCount":99},[],{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[2127],{"nctId":2128,"briefTitle":2129,"status":405,"phases":2130,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":2133,"conditions":2134,"interventions":2135},"NCT03594552","Modulation of the Brain Excitatory\u002FInhibitory (E\u002FI) Balance in Autism Spectrum Disorder (ASD)",[92],"2020-03-12","2018-02-01",87,[1457],[2113,2136],"Arbaclofen_30",{"intervention":2136,"totalTrials":95,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[2151],{"nctId":2128,"briefTitle":2129,"status":405,"phases":2152,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":2133,"conditions":2153,"interventions":2154},[92],[1457],[2113,2136],{"intervention":2156,"totalTrials":95,"cells":2157},"Dobutamine",{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[],{"trials":2165,"activeCount":99},[],{"trials":2167,"activeCount":99},[],{"trials":2169,"activeCount":99},[2170],{"nctId":2171,"briefTitle":2172,"status":532,"phases":2173,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2177,"interventions":2178},"NCT02888561","Haemodynamic Effects of Dobutamine and Nitrite in LV Dysfunction",[],"2018-06","2016-10",45,[34],[2156,2179],"Nitrite",{"intervention":2179,"totalTrials":95,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[],{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[2194],{"nctId":2171,"briefTitle":2172,"status":532,"phases":2195,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2196,"interventions":2197},[],[34],[2156,2179],{"intervention":2199,"totalTrials":95,"cells":2200},"Blood and urine samples",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":99},[],{"trials":2206,"activeCount":99},[],{"trials":2208,"activeCount":99},[],{"trials":2210,"activeCount":99},[],{"trials":2212,"activeCount":99},[2213],{"nctId":2214,"briefTitle":2215,"status":405,"phases":2216,"primaryCompletion":2217,"completion":2217,"start":2218,"enrollment":1715,"conditions":2219,"interventions":2223},"NCT06050616","Multimodal Longitudinal and Predictive Modelling to Understand Eating Disorder Development",[],"2024-08-12","2023-11-15",[2220,2221,2222],"Binge-Eating Disorder","Anorexia Nervosa","Bulimia Nervosa",[2199],{"intervention":2225,"totalTrials":95,"cells":2226},"MPH",{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":99},[],{"trials":2232,"activeCount":99},[],{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[2239],{"nctId":2240,"briefTitle":2241,"status":405,"phases":2242,"primaryCompletion":2243,"completion":2244,"start":2245,"enrollment":946,"conditions":2246,"interventions":2247},"NCT03709940","Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD)",[92],"2015-01-15","2016-03-10","2013-05-03",[1581],[2225]]